This document is a publication of a European patent application (EP3515945A1) by Regeneron Pharmaceuticals, Inc., detailing anti-STEAP2 antibodies, antibody-drug conjugates, and their uses. The publication date is March 11, 2026, and it falls under the International Patent Classification (IPC) codes related to antibodies, antibody-drug conjugates, and their therapeutic applications, specifically for cancer treatment.

As this is a patent publication, it does not impose direct compliance obligations on regulated entities in the same way as a rule or guidance. However, it is crucial for pharmaceutical and biotechnology companies, particularly those involved in antibody-drug conjugate development or cancer therapeutics, to be aware of this intellectual property. Companies should review the patent claims to ensure their own research, development, and commercial activities do not infringe upon this granted patent. Legal and R&D departments should monitor the patent's prosecution status and consider its implications for their product pipelines and freedom to operate.